EphemerisX Research

Deep research.

What happened after an FDA decision, reconstructed question by question from the FDA's letters and each company's SEC filings. Every quote is matched word for word to its source. How this research works →

Case INO-3107 and the PAPZIMEOS precedent: the record before October 30, 2026. →Case Jaypirca: what changed in the evidence behind four FDA decisions. →

Nasdaq: ALDX · Reproxalap

Aldeyra Therapeutics

reproxalap after the FDA's letters

9 questions · 16 source documentsOpen the web →

Nasdaq: CRMD · DefenCath (taurolidine and heparin)

CorMedix

DefenCath after the FDA's letters

9 questions · 20 source documentsOpen the web →

Nasdaq: OTLK · ONS-5010 (bevacizumab-vikg)

Outlook Therapeutics

ONS-5010 after the FDA's letters

9 questions · 21 source documentsOpen the web →

Nasdaq: REPL · RP1 (vusolimogene oderparepvec)

Replimune

RP1 after the FDA's letters

16 questions · 11 source documentsOpen the web →

Nasdaq: VRCA · VP-102 (cantharidin)

Verrica Pharmaceuticals

VP-102 after the FDA's letters

9 questions · 16 source documentsOpen the web →

Cross-investigations

Questions no single company's record can answer, followed across several.

What happens after a second FDA Complete Response Letter?Divergent outcome · Aldeyra Therapeutics · CorMedix · Outlook Therapeutics · Replimune · Verrica Pharmaceuticals
How did two programs move forward after repeat FDA letters without running a new trial?Comparable evidence · Outlook Therapeutics · Replimune
What is a Class 1 or Class 2 resubmission, and how did each play out in these records?Regulatory pathway · Aldeyra Therapeutics · CorMedix · Outlook Therapeutics · Replimune
When is one trial enough? How the FDA weighed the evidence in three programsComparable evidence · Aldeyra Therapeutics · Outlook Therapeutics · Replimune
What happens when an FDA letter turns on a contract manufacturer, not the drug?Shared concern · CorMedix · Verrica Pharmaceuticals
What did “no efficacy or safety issues” cover in these FDA letter announcements?Shared concern · CorMedix · Replimune · Verrica Pharmaceuticals

All cross-investigations →

Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →